F
F. Travert
Researcher at University of Paris
Publications - 25
Citations - 8750
F. Travert is an academic researcher from University of Paris. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 12, co-authored 22 publications receiving 8074 citations. Previous affiliations of F. Travert include Paris Diderot University & New York City Fire Department.
Papers
More filters
Journal ArticleDOI
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel,Stephen MacMahon,John Chalmers,Bruce Neal,Laurent Billot,Mark Woodward,Mark Woodward,Michel Marre,Mark E. Cooper,Paul Glasziou,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,C. Y. Pan,Neil R Poulter,Anthony Rodgers,Bryan Williams,Severine Bompoint,Bastiaan E. de Galan,Bastiaan E. de Galan,Rohina Joshi,F. Travert +26 more
TL;DR: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy.
Journal ArticleDOI
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Fiona Turnbull,Carlos Abraira,Robert J. Anderson,Robert J. Anderson,Robert P. Byington,John Chalmers,William C. Duckworth,Gregory W. Evans,Hertzel C. Gerstein,Rury R. Holman,Thomas E. Moritz,Bruce Neal,Toshiharu Ninomiya,Anushka Patel,Sanjoy K. Paul,F. Travert,Mark Woodward,Mark Woodward +17 more
TL;DR: Targeting more-intensive glucose lowering modestly reduced major macrovascular events and increased major hypoglycaemia over 4.4 years in persons with type 2 diabetes, and suggests that glucose-lowering regimens should be tailored to the individual.
Journal ArticleDOI
Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis
Ronan Roussel,F. Travert,Blandine Pasquet,Peter W.F. Wilson,Sidney C. Smith,Shinya Goto,Philippe Ravaud,Michel Marre,Avi Porath,Deepak L. Bhatt,P. Gabriel Steg +10 more
TL;DR: Metformin use may decrease mortality among patients with diabetes when used as a means of secondary prevention, including subsets of patients in whom met formin use is not now recommended.
Journal ArticleDOI
Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds
Sophia Zoungas,Sophia Zoungas,John Chalmers,Toshiharu Ninomiya,Qiang Li,M. E. Cooper,Stephen Colagiuri,Gregory R. Fulcher,B.E. de Galan,B.E. de Galan,Stephen B. Harrap,Pavel Hamet,Simon Heller,Stephen MacMahon,Michel Marre,Neil R Poulter,F. Travert,Anushka Patel,Bruce Neal,Mark Woodward,Mark Woodward +20 more
TL;DR: In patients with type 2 diabetes, HbA1c levels were associated with lower risks of macrovascular events and death down to a threshold of 7.0% and microv vascular events down toA threshold of 6.5%.
Journal ArticleDOI
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
B.E. de Galan,Sophia Zoungas,Sophia Zoungas,John Chalmers,Craig S. Anderson,Carole Dufouil,Carole Dufouil,Avinesh Pillai,M. E. Cooper,Diederik E. Grobbee,Maree L. Hackett,Pavel Hamet,Simon Heller,Liu Lisheng,Stephen MacMahon,Giuseppe Mancia,Bruce Neal,C. Y. Pan,Anushka Patel,Neil R Poulter,F. Travert,Mark Woodward,Mark Woodward +22 more
TL;DR: Cognitive dysfunction is an independent predictor of clinical outcomes in patients with type 2 diabetes, but does not modify the effects of BP lowering or glucose control on the risks of major cardiovascular events.